Worldwide Peptide Therapeutics Industry to 2030 - Featuring Apellis Pharmaceuticals, Eli Lilly and Novo Nordisk Among Others
08 Jul 2021
Small molecular drugCollaborate
Dublin, July 08, 2021 (GLOBE NEWSWIRE) -- The "Peptide Therapeutics Market by Type of Peptide, Route of Administration, Key Geographical Regions and Key Therapeutic Area: Industry Trends and Global Forecasts, 2021 - 2030" report has been added to ResearchAndMarkets.com's offering.
This report features an extensive study of the current market landscape of peptide therapeutics. The study also includes an elaborate discussion on the future potential of this evolving market.
Over the years, the rising popularity of biologics, such as peptide therapeutics, have led to an evident shift in the focus of the healthcare industry, from traditional small molecule-based interventions to upcoming, albeit complex, family of pharmacological interventions. The success of peptide therapeutics, so far, can be attributed to their clinical benefits, which include high target specificity, low toxicity and favorable safety profiles. Since 2017, over 10 peptide-based drugs have received marketing approvals across different regions of the world. Examples of recently approved peptide drugs include (in the reverse chronological order of approval) LupkynisT (2021), Mycappsa (2020), Scenesse (2019), Rybelsus (2019) and Vyleesi (2019). Further, more than 150 therapeutic peptides are currently under clinical investigation, while several novel leads are being evaluated in the early stages of research. In this context, it is also worth mentioning that peptide-based therapy products account for 5% of the global pharmaceutical revenues generated annually.
Presently, several drug developers, along with technology providers, are actively engaged in the development of novel peptide therapeutics, such as peptide drug conjugates and cell penetrating peptides. Innovation in this field of research is mostly focused on improving drug delivery methods, API stability, target affinity, and optimizing toxicity profiles. Several big pharma players have also demonstrated interest in peptide therapeutics and are investing both time and capital in this domain. Since 2019, more than USD 3 billion has been invested into companies that are involved in the development of various types of peptide drugs. In addition, the market is witnessing significant partnership activity; several licensing agreements, focused on drug development and commercialization, were recently inked between stakeholders in this industry.
Amongst other elements, the report features:
One of the key objectives of the report was to estimate the existing market size and future opportunity associated with peptide therapeutics, over the next decade. Based on the sales for approved peptide drugs, during the period 2015-2020, we have developed informed estimates on the evolution of the market over the coming decade. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of peptide (small, medium and large), [B] route of administration (intravenous, oral, subcutaneous, topical and others), [C] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World) and [D] key therapeutic area (metabolic diseases, oncological diseases, endocrine diseases, digestive and gastrointestinal diseases and others). In addition, the report provides value creation analysis of approved and clinical peptide-based therapies across different therapeutic areas.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Key Questions Answered
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. MARKET OVERVIEW
5. COMPETITIVE LANDSCAPE5.1. Chapter Overview5.2. Peptide Therapeutics: List of Developers5.2.1. Analysis by Year of Establishment5.2.2. Analysis by Company Size5.2.3. Analysis by Phase of Development and Geography (Logo Landscape)5.2.4. Key Players: Analysis by Number of Product Candidates5.3. Analysis by Company Size, Phase of Development and Geography (Heat Map
6. COMPANY PROFILES6.1. Chapter Overview6.2. Apellis Pharmaceuticals6.2.1 Company Overview6.2.2. Financial Information6.2.3 Pipeline Details6.2.4. Recent Developments and Future Outlook6.3. BioLineRx6.4. Eli Lilly6.5. FirstString Research6.6. Novo Nordisk6.7. Palatin Technologies6.8. RegeneRx Biopharmaceuticals6.9. Stealth BioTherapeutics6.10. Takeda6.11. Zealand Pharma
7. PEPTIDE THERAPEUTICS FOCUSED INITIATIVES OF BIG PHARMA7.1. Chapter Overview7.2. Top Pharmaceutical Companies: Peptide Therapeutics Focused Initiatives7.2.1. Analysis by Number of Amino Acids7.2.2. Analysis by Route of Administration7.2.3. Analysis by Therapeutic Area7.3. Benchmark Analysis of Key Parameters7.3.1. Spider Web Analysis: Pipeline Strength7.3.2. Spider Web Analysis: Partnerships7.3.3. Spider Web Analysis: Investments7.3.4. Spider Web Analysis: Clinical Trials7.4. Benchmark Analysis of Big Pharmaceutical Players7.4.1. Spider Web Analysis: Novo Nordisk7.4.2. Spider Web Analysis: Amgen7.4.3. Spider Web Analysis: Takeda7.4.4. Spider Web Analysis: Eli Lilly7.4.5. Spider Web Analysis: Johnson and Johnson
8. PARTNERSHIPS AND COLLABORATIONS8.1. Chapter Overview8.2. Partnership Models8.3. Peptide Therapeutics: List of Partnerships and Collaborations8.3.1. Analysis by Year of Partnership8.3.2. Analysis by Type of Partnership8.3.3. Analysis by Year and Type of Partnership8.3.4. Analysis by Type of Peptide8.3.5. Analysis by Route of Administration8.3.6. Analysis by Type of Partnership and Route of Administration8.3.7. Analysis by Type of Partnership, Type of Peptide and Route of Administration8.3.8. Analysis by Phase of Development8.3.9. Analysis by Type of Partnership and Phase of Development8.3.10. Analysis by Therapeutic Area8.3.11. Analysis by Year, Type of Partnership and Therapeutic Area (Grid8.4. Most Active Players: Analysis by Number of Partnerships8.5. Regional Analysis8.5.1. Intracontinental and Intercontinental Agreements8.5.2. Local and International Agreements
9. FUNDING AND INVESTMENT ANALYSIS9.1. Chapter Overview9.2. Types of Funding9.3. Peptide Therapeutics: Funding and Investment Analysis9.3.1. Analysis by Number of Funding Instances9.3.2. Analysis by Amount Invested9.3.3. Analysis by Type of Funding9.3.4. Analysis by Year and Type of Funding9.3.5. Analysis of Amount Invested by Geography9.3.6. Most Active Players: Analysis by Number of Funding Instances and Amount9.3.7. Key Investors: Analysis by Number of Funding Instances9.3.8. Analysis by Phase of Development9.3.9. Analysis by Therapeutic Area
10. CLINICAL TRIAL ANALYSIS10.1. Chapter Overview10.2. Scope and Methodology10.3. Peptide Therapeutics: Clinical Trial Analysis10.3.1. Analysis by Trial Registration Year10.3.2. Analysis by Trial Status10.3.3. Analysis by Trial Phase10.3.4. Analysis by Trial Recruitment Status10.3.5. Analysis by Trial Registration Year and Enrolled Patient Population10.3.6. Analysis by Study Design10.3.7. Analysis by Type of Sponsor / Collaborator10.3.8. Most Active Players: Analysis by Number of Registered Trials10.3.9. Emerging Focus Area10.3.10. Analysis by Therapeutic Area10.3.11. Geographical Analysis by Number of Registered Trials10.3.12. Geographical Analysis by Enrolled Patient Population
11. CLINICAL AND COMMERCIAL ATTRACTIVENESS ANALYSIS11.1. Chapter Overview11.2. Methodology11.2.1. Assumptions and Key Parameters11.3. Affiliated Insights11.3.1. Clinical and Commercial Attractiveness Analysis: Autoimmune Diseases11.3.2. Clinical and Commercial Attractiveness Analysis: Cardiovascular Diseases11.3.3. Clinical and Commercial Attractiveness Analysis: Central Nervous System11.3.4. Clinical and Commercial Attractiveness Analysis: Digestive and Gastrointestinal 11.3.5. Clinical and Commercial Attractiveness Analysis: Endocrine Diseases11.3.6. Clinical and Commercial Attractiveness Analysis: Genetic Diseases11.3.7. Clinical and Commercial Attractiveness Analysis: Hematological Diseases11.3.8. Clinical and Commercial Attractiveness Analysis: Infectious Diseases11.3.9. Clinical and Commercial Attractiveness Analysis: Inflammatory Diseases11.3.10. Clinical and Commercial Attractiveness Analysis: Metabolic Diseases11.3.11. Clinical and Commercial Attractiveness Analysis: Oncological Diseases11.3.12. Clinical and Commercial Attractiveness Analysis: Ophthalmic Diseases11.3.13. Clinical and Commercial Attractiveness Analysis: Other Diseases
12. CASE STUDY: CONTRACT SERVICES LANDSCAPE12.1.1. Chapter Overview12.2. Role of Service Providers12.2.1. List of Peptide CROs12.2.2. List of Platform Providers12.2.3. List of Peptide CMOs12.2.3.1. List of Custom Peptide Manufacturers12.3. Advantages of Outsourcing12.4. Risks and Challenges Associated with Outsourcing
13. CASE STUDY: NOVEL PEPTIDE THERAPEUTICS13.1. Chapter Overview13.2. Overview of Novel Peptide Therapeutics13.3. Advantages and Applications of Novel Peptide Therapeutics13.4. Key Challenges Associated with Novel Peptide Therapeutics
14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
15. CONCLUDING REMARKS
16. APPENDIX I: LIST OF APPROVED PEPTIDE THERAPEUTICS (2000-2012)
17. APPENDIX II: TABULATED DATA
18. APPENDIX III: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.